This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Drug Therapy, Other  • Leukemias/ Lymphomas  • Immunologic Disorders  • Alert me on articles by topic

Tracy Hampton, PhD

JAMA. 2007;297:457-458.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Orlando—Novel targeted compounds used alone or in combination with current therapies to treat leukemias and lymphomas have generated positive results in studies highlighted at the recent annual meeting of the American Society of Hematology.

Over the years, researchers and clinicians have come to understand the biochemical aspects of hematology better than most disciplines of medicine.

Researchers are currently testing how well new anticancer therapies and some previously approved drugs target acute myeloid leukemia (above) and other blood cancers. (Photo credit: Andrejs Liepins/http://www.sciencesource.com)

"We're in a very privileged opportunity now to move those great advances in understanding into the clinic," said Kenneth Kaushansky, MD, current president-elect of the American Society of Hematology and chair of the department of medicine at the University of California, San Diego. Research presented at the meeting revealed "how we're taking our knowledge of the workings of tumors and leukemias to . . . [Full Text of this Article]

NEW CML DRUG